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Chimaeric muscarinic acetylcholine r ceptors (mAChR) in which corresponding portions of mAChR I and mAChR II 
are replaced with each other have been produced in Jfenopus oocytes by expression of cDNA constructs encoding them. 
Functional analysis of the chimaeric mAChRs indicates that a region mostly comprising the putative cytoplasmic portion 
between the proposed transmembrane segments V and VI is involved in selective coupling of mAChR I and mAChR 
II with different effector systems. In contrast, the exchange of this region between mAChR I and mAChR II does not 
significantly affect he antagonist binding properties of the two mAChR subtypes. 
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1. INTRODUCTION 
The muscarinic acetylcholine receptor mediates 
a variety of cellular responses through the action 
of guanine nucleotide-binding regulatory proteins 
(G-proteins) [11. Accumulating evidence indicates 
that molecularly distinct mAChR subtypes are 
selectively coupled with different effector systems, 
albeit not exclusively. Expression in Xenopus 
oocytes of cloned DNAs encoding four individual 
mAChR subtypes has revealed that mAChR I 
and mAChR III mediate activation of a 
Ca2+-dependent C1- current, whereas mAChR II 
and mAChR IV principally induce activation of 
Na ÷ and K ÷ currents in a Ca2+-independent man- 
ner [2-4]. Expression studies in mammalian cells 
have further shown that mAChR I and mAChR III 
are coupled efficiently with phosphoinositide 
hydrolysis [5-7], intracellular Ca 2÷ release [8], ac- 
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tivation of Ca2+-dependent K ÷ currents [5,8,9] and 
inhibition of the M-current [5,8], whereas mAChR 
II and mAChR IV are linked preferentially with 
adenylate cyclase inhibition [6,10]. It has also been 
revealed that the sensitivity to and the binding af- 
finity for agonist of mAChR III are about one 
order of magnitude higher than those of mAChR 
I [4,8]. Moreover, different sensitivities to per- 
tussis toxin of the cellular responses mediated by 
individual mAChR subtypes suggest that the 
response induced by mAChR I or mAChR III and 
that induced by mAChR II or mAChR IV occur 
through distinct G-proteins [5,10,11]. The an- 
tagonist binding properties of individual mAChR 
subtypes expressed in Xenopus oocytes [2,3,12] 
show that mAChR I, mAChR II and mAChR III 
correspond most closely to the pharmacologically 
defined M1 (I), M2 cardiac (II) and M2 glandular 
(III) subtypes [13-15], respectively. This, together 
with the differential tissue distribution of the 
mRNAs encoding the individual mAChR species 
[2,16-19], indicates that the mAChR heterogenei- 
ty in tissues with respect o antagonist binding is 
attributable to the presence of distinct mAChR 
gene products by themselves or in various com- 
binations. 
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The  present  invest igat ion has been designed to 
local ize the reg ion o f  the mAChR molecules  
respons ib le  for  selective coup l ing  with d i f ferent  ef- 
fector  systems. For  this purpose,  ch imaer ic  
mAChR molecu les  with d i f ferent  combinat ions  o f  
mAChR I and mAChR II have been produced  in 
Xenopus  oocytes  by express ion o f  the corre-  
spond ing  cDNAs  and have  been compared  with the 
parenta l  mAChRs  with respect to acety lchol ine 
(ACh) - induced  current  responses and antagonis t  
b ind ing  propert ies .  
2. MATERIALS  AND METHODS 
cDNAs encoding chimaeric mAChRs were constructed as 
follows. The 2.5-kilobasepair (kb) Pvul/SaclI fragment and the 
61-basepair (bp) Sacll/Fokl fragment from the plasmid 
pSPBM1 [3], the -4.2-kb Drall/PvuI fragment from the 
plasmid pSPHM45 [3] and the synthetic oligodeox- 
yribonucleotide 
5 ' -GGACCATCTTGGCTATTCTGCTAGCTTTCATCATCACTTGG-3 '  
3 ' -GTAGAACCGATAAGACGATCGAAAGTAGTAGTGAACCCGG-5 '  
(prepared with an automatic DNA synthesizer, Applied 
Biosystems) were ligated to yield the plasmid pSPMC2. The 
166-bp NsiI/XmaI fragment from pSPHM45, the 542-bp 
BstXl/BgllI fragment from pSPBM1 and the synthetic 
oligodeoxyribonucleotide 
5 ' -CCGGGAAAAGAAAGTGACCAGGACGCTGAGCGCCATCCTG-3 '  
3 ' -CTTTTCTTTCACTGGTCCTGCGACTCGCGGTA-5 '  
were ligated and cleaved by Nsil and BgllI. The resulting 748-bp 
fragment was ligated with the 2.5-kb Pvul/NsiI fragment from 
pSPHM45 and the -2.5-kb BgllI/Pvul fragment from 
pSPBM1 to yield the plasmid pSPMC4, The 377-bp 
Sau3Al/NsiI fragment from pSPHM45 and the synthetic 
oligodeoxyribonucleotide 
5 ' -CATGGCCGCCTTCTACCTCCCTGT-  3 ' 
3 ' -CGGCGGAAGATGGAGGGACACTAG-  5 ' 
were ligated and cleaved by Nsil. The resulting 401-bp fragment 
was ligated with the -5.8-kb NsiI/HindlII fragment from 
pSPHM45 and the 756-bp Hindll I/Ncol fragment from 
pSPBM1 to yield the plasmid pSPMC7. The 376-bp 




were ligated and cleaved by Sacll. The resulting 430-bp frag- 
ment was ligated with the -3.l-kb SaclI/Pvul fragment from 
pSPBM1 and the 2.0-kb PvuI/BclI fragment from pSPHM45 
to yield the plasmid pSPMC8. The 1.4-kb SphI/Nsil fragment 
from pSPMC7 and the -4.2-kb Nsil/Sphl fragment from 
pSPMC4 were ligated to yield the plasmid pSPMC9. The 
plasmid pmACR84 ]2] was cleaved by MstlI, treated with T4 
DNA polymerase in the presence of the four deox- 
yribonucleoside triphosphates (blunt-ended), ligated with the 
synthetic EcoRl linker 5'-CCGGAATTCCGG-3' and cleaved 
by EcoRl and BgllI. The resulting 1.7-kb EcoRl/Bglll frag- 
ment was ligated with the -0.9-kb Bglll/Pvull fragment from 
pmACR84 and the 3.0-kb SmaI/EcoRI fragment from the 
plasmid pSP65 [20] to yield the plasmid pSPM26, pSPMC9 was 
cleaved by Mstll, blunt-ended, ligated with the synthetic EcoRl 
linker and cleaved by EcoRl and Xbal. The resulting -2.6-kb 
EcoRl/Xbal fragment was ligated with the 3.0-kb XbaI/EcoR1 
fragment from pSPM26 to yield the plasmid pSPMC9-1, which 
contained the same cDNA insert as pSPMC9, except hat a por- 
tion of the 5'-noncoding region (nucleotide residues - 167 to 
-74) was deleted. The 4.l-kb XbaI/SaclI fragment from 
pSPMC8 and the -2.7-kb SaclI/Xbal fragment from pSPMC2 
were ligated to yield the plasmid pSPMC10. All the constructs 
were confirmed by sequencing the regions derived from the syn- 
thetic oligodeoxyribonucleotides according to [21,22] and by 
restriction endonuclease analysis. 
mRNAs specific for the chimaeric mAChRs MC2, MC4, 
MC7, MCS, MC9 and MC10 were synthesized by transcription 
in vitro [20,23] using XbaI-cleaved pSPMC2, pSPMC4, 
pSPMC7, pSPMC8, pSPMC9-1 and pSPMC10 as templates, 
respectively, unless otherwise indicated, mRNAs specific for 
mAChR I and mAChR II were synthesized as in [3]. Each of the 
mRNAs was injected into Xenopus laevis oocytes. The mRNA 
concentration used for injection was 10 ng//zl for MCI0, 
20 ng//zl for MC8 or 1/zg//tl for the other chimaeric and paren- 
tal mAChRs, unless otherwise indicated, and the average 
volume injected per oocyte was -40 nl. The injected oocytes 
were incubated at 19°C for 2 days as in [2], except that the dura- 
tion of incubation was 3 days for some of the measurements of 
(-)-[3H]quinuclidinyl benzilate (QNB) binding in cell extracts 
and its displacement by unlabelled antagonists. These 
measurements were carried out as in [12]. The procedures used 
for the assay of ( - )-[3H]N-methylscopolamine (NMS) binding 
on the cell surface and for the measurement of ACh-activated 
currents in Ringer's solution have been described in [2]. 
3. RESULTS AND DISCUSSION 
Fig.1 schemat ica l ly  shows the structures o f  dif- 
ferent  ch imaer ic  mAChRs  in which cor respond ing  
por t ions  o f  porc ine mAChR I and mAChR II are 
rep laced with each other ,  cDNAs  encod ing  these 
ch imaer ic  mAChRs  were const ructed and 
t ranscr ibed in v i tro.  Each  o f  the result ing mRNAs  
was in jected into Xenopus  oocytes to produce  the 
respect ive ch imaer ic  mAChRs .  
F ig .2  shows the ACh- induced  current  responses 
observed at -70  mV membrane  potent ia l  in 
oocytes  imp lanted  with the d i f ferent  ch imaer ic  
mAChRs  (C -G)  and with the parenta l  mAChR I 
120 
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Fig.1. Structures of chimaeric mAChRs composed of porcine 
mAChR I (filled boxes) and mAChR II sequences (open boxes). 
Junctional sequences common to mAChR I and mAChR II are 
indicated by both boxes. The structures of chimaeric mAChRs 
are diagrammatically shown such that the putative 
transmembrane s gments I -VI I  are aligned [2,16]; the fact that 
mAChR II differs from mAChR I in the lengths of the amino- 
terminal region preceding segment I ( -2  amino acid residues), 
the region between segments V and VI (+ 24 residues) and the 
carboxy-terminal region following segment VII ( -  16 residues) 
is ignored. The compositions of the individual chimaeric 
mAChRs are as follows (the numbers in parentheses indicate 
amino acid numbers [2,16]; the junctional sequences common 
to mAChR I and mAChR II are represented by amino acid 
numbers of mAChR I): MC2, mAChR I (1-366) and mAChR 
II (389-466); MC4, mAChR II 0-386)  and mAChR I 
(365-460); MCS, mAChR II (1-200) and mAChR I (203-460); 
MC9, mAChR I (1-201), mAChR I1 (200-386) and mAChR I 
(365-460); MC10, mAChR II (1-200), mAChR I (203-366) 
and mAChR II (389-466). In addition, MC7 composed of 
mAChR I (1-201) and mAChR II (200-466) was used (see the 
text). 
(A)  and  mAChR II  (B).  The  ACh-act ivated  inward  
cur rent  med ia ted  by  the  ch imaer ic  mAChR MC2,  
MC8 or  MC10 was  osc i l l a to ry  in nature  
( f ig .2C ,E ,G ,  le f t  t races)  and  was  a lmost  complete -  
ly abo l i shed  by  in t race l lu la r  in jec t ion  o f  the  
ca lc ium-che la t ing  agent  EGTA ( f ig .2C ,E ,G ,  r ight  
t races) .  On  the  o ther  hand,  a typ ica l  ACh response  
med ia ted  by  the  ch imaer ic  mAChR MC4 or  MC9 
Fig.2. Effect of EGTA on ACh-activated currents in Xenopus 
oocytes injected with the mRNA specific for mAChR I (A), 
mAChR II (B), MC2 (C), MC4 (D), MC8 (E), MC9 (F) or 
MC10 (G). Whole-cell currents activated by bath application of 
1/~M ACh were recorded under voltage clamp at -70  mV 
membrane potential in Ringer's olution before (left traces) and 
after intracellular injection of EGTA (right traces). Inward 
current is downward. The duration of ACh application is 
indicated by bars without taking into account he dead-space 
time in the perfusion system ( -6  s). EGTA was injected 
ionophoretically into the oocytes as in [3], except that the 
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comprised an initial smooth inward current follow- 
ed by an oscillatory component (fig.2D,F, left 
traces). The oscillatory current elicited by MC4 or 
MC9 varied in amplitude among the oocytes tested 
and was undetected in some of them. The smooth 
current evoked by MC4 or MC9 was virtually 
unaffected by intracellular injection of EGTA, 
whereas the oscillatory current disappeared after 
this treatment (fig.2D,F, right traces). Thus, MC2, 
MC8 and MC10, in which the putative cytoplasmic 
portion between the proposed transmembrane 
segments V and VI is derived from mAChR I, 
mediate an ACh response similar to that mediated 
by mAChR I (fig.2A; see also [2,3]). In contrast, 
MC4 and MC9, which share this portion with 
mAChR II, elicit an ACh response similar to that 
induced by mAChR II (fig.2B; see also [3]). 
The average peak inward current activated by 
1/zM ACh at -70  mV membrane potential was 
much larger in oocytes implanted with MC2, MC8 
or MC10 than in oocytes implanted with MC4 or 
MC9 (fig.2 and table 1). The difference was more 
than two orders of magnitude in terms of average 
current per unit amount of ( - ) - [3H]NMS binding 
on the cell surface (an estimate of receptor density) 
(table 1). The average amplitudes of current 
response per unit amount of ( - ) - [3H]NMS 
binding observed for MC2, MC8 and MC10 were 
comparable to that of mAChR I, whereas similar 
values were obtained for MC4, MC9 and mAChR 
II (table 1). It is to be noted that the concentrations 
of the mRNAs injected (10 ng/#l to 1 #g/#l) were 
chosen so that the ( - ) - [3H]NMS binding activity 
on the cell surface was within a range where the 
average current activated by 1/~M ACh was pro- 
portional to the binding activity; this propor- 
tionality was not examined for M9 which showed 
only a small current response even when the 
mRNA concentration was 1/tg//A. Oocytes in- 
jected with the mRNA encoding the chimaeric 
mAChR MC7 (see the legend to fig.l), which is 
almost a 'mirror image' of MC8, exhibited no 
detectable ( - ) - [3H]NMS binding activity on the 
cell surface and did not respond to ACh. 
The ACh response mediated by MC9 and MC10 
was further characterized. The latency of the ACh 
response in MC9-implanted oocytes was shorter 
than that in MC10-implanted oocytes, the former 
being attributable mostly to the dead-space time in 
the perfusion system ( -6  s). The ACh response in 
Table 1 
Functional expression of chimaeric mAChRs in Xenopus 
oocytes 
mAChR ( - )-[3H]NMS ACh-activated Current per 
binding on cell peak inward unit amount 
surface (fmol current of (-)-[3H]- 
per oocyte) (nA) NMS binding 
(nA/fmol) 
mAChR I 3.2 _+ 2.0 (3) 2400 +_ 1210 (32) 750 
mAChR II 87.1 _+ 37.3 (5) 210 _+ 170 (28) 2.4 
MC2 1,0 + 0.2 (3) 1840 + 760 (41) 1840 
MC4 70,1 _+ 29.1 (6) 163 _+ 85 (30) 2.3 
MC8 6.0 _+ 0.8 (3) 2520 + 1370 (20) 420 
MC9 11,5 + 7.1 (5) 22 + 15 (20) 1.9 
MC10 3,2 +_ 1.2 (5) 2910 _+ 1300 (33) 909 
Data are given as means _+ SD; numbers in parentheses refer to 
the number of experiments for (-)-[3H]NMS binding activity 
or the number of oocytes for current measurements. Whole-cell 
currents activated by 1/zM ACh (bath-applied for 30 s) were 
recorded under voltage clamp at - 70 mV membrane potential 
in Ringer's solution. Our detectable limits were -0.8 fmol per 
oocyte for (-)-[3H]NMS binding activity and -8  nA for ACh- 
activated current. Noninjected oocytes showed neither ( - ) -  
[3H]NMS binding nor ACh-activated current 
MC10-implanted oocytes occurred after an addi- 
tional delay (3 + 2 s, mean _+ SD, n = 25). The 
reversal potential of the oscillatory current elicited 
by MC10 in Ringer's solution was -24  _+ 1 mV 
(n = 3), which is close to the equilibrium potential 
of chloride ions in Xenopus oocytes [24]. The 
oscillatory current in MC9-implanted oocytes was 
reversed in polarity at a potential around 
-25  mV, whereas the reversal potential of the 
smooth current was around 10 mV. In 
MC9-implanted oocytes loaded with EGTA, the 
reversal potential of the smooth current was 9 _+ 
1 mV (n = 7). These results provide further 
evidence that the ACh response mediated by MC10 
is similar to that mediated by mAChR I, whereas 
MC9 and mAChR II elicit a similar response. 
The antagonist binding properties of the 
chimaeric mAChRs were examined in comparison 
with those of mAChR I and mAChR II, using 
oocyte extracts. The apparent dissociation con- 
stant (Kd) for ( - ) - [3H]QNB was similar for all the 
chimaeric and parental mAChRs (see the legend to 
fig.3), except for MC2 whose Kd value could not be 
evaluated because of its low binding activity. The 
apparent K~ values of MC4, MC8, MC9 and MC10 
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Fig.3. Effects of pirenzepine (A) and AF-DX 116 (B) on ( - ) -  
[3H]QNB binding in extracts from Xenopus oocytes injected 
with the mRNA specific for mAChR I (©), mAChR II (,x), 
MC4 ( , ) ,  MC8 ( i ) ,  MC9 (o) or MCI0 (A). The mRNA 
specific for MC9 was synthesized using Xbal-cleaved pSPMC9 
as a template (see section 2). The concentration of each mRNA 
injected was 1 izg//A. Data are from 3-5 experiments. Values 
for 100% and 00/0 binding were determined by measurements in 
the absence of antagonist and in the presence of 10/~M 
atropine, respectively. The 0% values [89-210 dpm (©), 
84-155 dpm (zx), 81-144 dpm (.) ,  93-173 dpm (,,), 
116-155 dpm (o) or 127-195 dpm (,t)] were 5-26% (o), 
1-10% (zx), 2 -5% (*), 5-7% (- ) ,  23-380/0 (e) or 0.7-3°70 
(A) of the 100°70 values. The theoretical curves have been drawn 
by nonlinear least-squares analysis as in [2]. The ICso values of 
pirenzepine and AF-DX 116 were 79.4 nM and 17.8,uM for 
mAChR I, 3.24,aM and 3.39,uM for mAChR I1, 631 nM and 
4.37 ,uM for MC4, 380 nM and 3.89/~M for MC8, 81.3 nM and 
13.5,aM for MC9, and 3.31,uM and 2.45/zM for MC10, 
respectively. The Kd values for (-)-[3H]QNB, obtained by 
Scatchard analysis from 3 experiments each, were 84 _+ 55 pM 
for mAChR I [12], 130 +_ 17 pM for mAChR I1 [12], 143 + 
60 pM for MC4, 100 + 64 pM for MC8, 185 _+ 76 pM for MC9 
and 129 _+ 27 pM for MCI0. The Kd values for pirenzepine and 
AF-DX 116, calculated according to [25], were 13 nM and 
2.9/zM for mAChR I, 0.75/zM and 0.79/zM for mAChR II, 
0.16/zM and 1.1 ,uM for MC4, 72 nM and 0.73/zM for MC8, 
24 nM and 4.1/~M for MC9, and 0.76/zM and 0.57/~M for 
MCI0, respectively. 
for the selective antagonists pirenzepine and AF- 
DX 116 were obtained by measuring displacement 
of ( - ) - [3H]QNB binding by increasing concentra- 
tions of the antagonists (fig.3). MC9 showed a 
high affinity for pirenzepine (Kd = 24 nM) similar 
to that of mAChR I (Kd = 10-18 nM; see also 
[2,3,12]) and a low affinity for AF-DX 116 (Kd = 
4.1 /zM) similar to that of mAChR I (Kd = 
1.8-2.9/zM; see also [3,12]). In contrast, MC10 
showed a low affinity for pirenzepine (Kd = 
0.76/zM) similar to that of mAChR II (Kd = 
0.50-0.75/zM; see also [3,12]) and a high affinity 
for AF-DX 116 (Ko = 0.57/zM) similar to that of 
mAChR II (Kd = 0.36-0.79/zM; see also [3,12]). 
These results indicate that the region comprising 
mostly the putative cytoplasmic portion between 
the proposed transmembrane s gments V and VI is 
not involved in binding to the selective antagonists. 
On the other hand, MC4 and MC8 showed an in- 
termediate affinity for pirenzepine (Ko = 
0.072-0.16/zM) and an intermediate or high af- 
finity for AF-DX 116 (Kd = 0.73--1.1/zM). These 
results may indicate that both a region containing 
the putative transmembrane s gments I -V  and a 
region containing the putative transmembrane 
segments VI and VII are involved in antagonist 
binding. Affinity labelling and peptide mapping 
studies suggest hat the ligand binding site of the 
mAChR is located deep within the membrane [26]. 
Similarly, an involvement of putative transmem- 
brane segments in ligand binding has been reported 
for adrenergic receptors [27-29]. 
The present investigation reveals that the 
chimaeric mAChR MC10, in which only the seg- 
ment composed of amino acid residues 203-364 of 
mAChR I is substituted for the corresponding seg- 
ment of mAChR II (amino acid residues 201-386), 
mediates an ACh response indistinguishable from 
that mediated by mAChR I. Our results also show 
that the chimaeric mAChR MC9, which is almost 
a 'mirror image' of MC10 (amino acid residues 
200-386 of mAChR II substituted for the cor- 
responding residues 202-364 of mAChR I), evokes 
an ACh response indistinguishable from that in- 
duced by mAChR II. Thus, it is concluded that the 
region of the mAChR molecules comprising the 
carboxy-terminal third of the proposed transmem- 
brane segment V and the following putative 
cytoplasmic portion before the proposed 
transmembrane S gment VI contains a determinant 
of selective coupling with different effector 
systems. In contrast, the exchange of this region 
between mAChR I and mAChR II does not 
significantly;affect the antagonist binding proper- 
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ties of the two mAChR subtypes. The amino acid 
sequence of the putative cytoplasmic portion be- 
tween the proposed transmembrane s gments V 
and VI is divergent among the mAChR subtypes 
[2,12,16-18,30,31]. However, some sequence 
homology is noted in this portion between mAChR 
I and mAChR III  as well as between mAChR II 
and mAChR IV, particularly in the vicinity of 
segments V and VI. Furthermore, it has been 
shown that mAChR I and mAChR III  are coupled 
with the same effector systems as are mAChR II 
and mAChR IV [2-10]. Thus, it seems reasonable 
to assume that a region adjacent o the carboxyl- 
terminus of segment V and a region adjacent o the 
amino-terminus of segment VI are responsible for 
selective coupling of mAChR subtypes with dif- 
ferent effector systems, probably through interac- 
tion with distinct G-proteins. 
Recent studies with chimaeras between the 15'2- 
and o~2-adrenergic receptors have shown that the 
specificity for coupling with the stimulatory G- 
protein lies within a region extending from the 
amino-terminus of segment V to the carboxyl- 
terminus of segment VI [29]. It has also been 
reported that deletion of an amino-terminal or a 
carboxy-terminal sequence of the putative 
cytoplasmic portion between segments V and VI in 
the ~2-adrenergic receptor leads to loss of 
stimulatory G-protein activation [32]. Further- 
more, a single amino acid substitution in the por- 
tion between segments V and VI of rhodopsin has 
been shown to prevent activation of transducin 
[33]. Thus, the conclusion that a region mostly 
comprising the putative cytoplasmic portion be- 
tween segments V and VI is involved in selective f- 
fector coupling may be generally valid for 
G-protein-coupled receptors. 
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